The COX- inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in Mycobacterium tuberculosis infection by Kristian Tonby et al.
RESEARCH ARTICLE Open Access
The COX- inhibitor indomethacin reduces
Th1 effector and T regulatory cells in vitro
in Mycobacterium tuberculosis infection
Kristian Tonby1,2*, Ida Wergeland3, Nora V. Lieske4, Dag Kvale1,2,5, Kjetil Tasken2,4,5,6 and Anne M. Dyrhol-Riise1,2,3,5
Abstract
Background: Tuberculosis (TB) causes a major burden on global health with long and cumbersome TB treatment
regimens. Host-directed immune modulating therapies have been suggested as adjunctive treatment to TB
antibiotics. Upregulated cyclooxygenase-2 (COX-2)-prostaglandin E2 (PGE2) signaling pathway may cause a
dysfunctional immune response that favors survival and replication of Mycobacterium tuberculosis (Mtb).
Methods: Blood samples were obtained from patients with latent TB (n = 9) and active TB (n = 33) before initiation of
anti-TB chemotherapy. COX-2 expression in monocytes and ESAT-6 and Ag85 specific T cell cytokine responses (TNF-α,
IFN-γ, IL-2), proliferation (carboxyfluorescein succinimidyl ester staining) and regulation (FOXP3+ T regulatory cells) were
analysed by flow cytometry and the in vitro effects of the COX-1/2 inhibitor indomethacin were measured.
Results: We demonstrate that indomethacin significantly down-regulates the fraction of Mtb specific FOXP3+ T
regulatory cells (ESAT-6; p = 0.004 and Ag85; p < 0.001) with a concomitant reduction of Mtb specific cytokine
responses and T cell proliferation in active TB. Although active TB tend to have higher levels, there are no significant
differences in COX-2 expression between unstimulated monocytes from patients with active TB compared to latent
infection. Monocytes in both TB groups respond with a significant upregulation of COX-2 after in vitro stimulation.
Conclusions: Taken together, our in vitro data indicate a modulation of the Th1 effector and T regulatory cells in Mtb
infection in response to the COX-1/2 inhibitor indomethacin. The potential role as adjunctive host-directed therapy in
TB disease should be further evaluated in both animal studies and in human clinical trials.
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Background
Infection with Mycobacterium tuberculosis (Mtb) causes a
major burden on global health with 9 million people suffer-
ing from tuberculosis (TB) disease and with 1.5 million
deaths every year [1]. The current TB treatment strategies
consist of long lasting multiple drug regimens with risk of
serious side-effects and development of multi-drug resistant
TB (MDR-TB). Host-directed therapies (HDTs) in conjunc-
tion with standard anti-TB drug regimens may reduce the
duration of therapy, achieve better treatment outcomes,
lower the risk of developing further drug resistance and
decrease the chances of relapse or reinfection [2, 3].
In chronic infections such as TB, immune-mediated tissue
injury may become more detrimental than the pathogen
itself and the immune system have evolved mechanisms to
balance pro and anti-inflammatory signals [4]. FOXP3+ T
regulatory cells (Tregs) are involved in the regulation of in-
flammatory processes and exert immunosuppressive func-
tions by cell contact-dependent suppression of CD4+ T cells
and by secretion of inhibitory cytokines and soluble factors
[5, 6]. Tregs may dampen protective immunity facilitating
pathogen multiplication and dissemination [7] and may also
limit vaccine immunogenicity [8]. Thus, targeting of Tregs
may have potential as host directed adjunctive therapies [9].
Prostaglandin E2 (PGE2) is generated by the constitutive
cyclooxygenase 1 (COX-1) and the inducible cyclooxygenase
2 (COX-2) enzymes and is regarded as a key mediator of im-
munopathology with immune regulatory effects in chronic
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infections [10, 11]. Macrophages and monocytes up-regulate
COX-2 enzymes in response to inflammatory signals and
are thereby major producers of PGE2 and other eicosanoids
[12]. Monocytes as well as adaptive Tregs seem to inhibit
effector T cell functions and suppress T cell immune re-
sponses by a COX-2-PGE2-dependent mechanism [13–15].
It has been shown that highly expressed COX-2 in malig-
nant tissue is associated with poor prognosis and outcome
in cancer disease [16, 17]. However, no data exists on COX-
2 expression of immune cells in human TB disease.
Standard TB antibiotics are directed against the pathogen,
but various host directed immune therapies, including
reduction of PGE2 production by COX- inhibitors (COX-i)
has potential to become part of a treatment strategy for
resistant or clinically complicated TB cases or as part of a
TB vaccination scheme [18–20]. Accordingly, studies of TB
animal models have shown that targeting PGE2 with COX-i
have significant impact on the immune responses and
outcome of disease [21–25]. Based on these data, it is
suggested that a human intervention study with anti-
inflammatory drugs given in combination with anti-TB
chemotherapy should be performed [24]. Clinical trials in
HIV infected patients have also shown that COX-i improve
Tcell mediated immune responses [26–28].
Indomethacin is a widely used non-steroidal anti-
inflammatory drug (NSAID) of the methylated indole class
with analgesic and antipyretic properties exerting its
pharmacological effects by inhibiting the synthesis of prosta-
glandins via the arachidonic acid pathway [29]. Indometh-
acin inhibits both COX-1 and COX-2 with greater
selectivity for COX-1 [30] and due to water soluble charac-
teristics the compound is practical to use in in vitro studies.
Indomethacin has previously been shown to increase the
bactericidal activity of Mtb infected macrophages [31] and
to improve T cell proliferative responses in HIV-infected pa-
tients [28], but to our knowledge the effect of indomethacin
on Tcell responses has not been studied in TB infection.
The objective of this study was to analyze COX-2
expression in monocytes from patients with latent and
active TB and to explore the in vitro effects of the COX-i
indomethacin on Mtb-specific T cell responses and regula-
tion. We show that indomethacin down-regulates Mtb anti-
gen stimulated Tregs, antigen induced cytokine responses,
in particular TNF-α+ cells, and Tcell proliferation. Our data
suggest a potential role for COX-i in modulation of immune
responses in TB infection. However, the functional conse-
quences of our data need to be further evaluated and the
potential for COX-i as HDT in TB infection should be ex-
plored in both animal studies and in human clinical trials.
Methods
Study participants
Ten patients with active TB disease (ATB) and nine pa-
tients with latent TB (LTB) were recruited from Haukeland
University hospital, Bergen, Norway (cohort A). Additional,
23 patients with active TB disease were recruited from
Oslo University hospital, Oslo, Norway (cohort B). Table 1
summarizes demographic and clinical patient characteris-
tics. All patients were HIV uninfected. The diagnosis of
active TB was based on a positive Mtb culture or on
clinical and radiological findings. Subjects with a positive
QuantiFERON®-TB test and with no signs of active TB
based on X-ray, sputum or biopsy examination and clinical
evaluation were defined as LTB.
Sample processing
Blood samples were obtained before initiation of anti-TB
chemotherapy. Peripheral blood mononuclear cells (PB
MCs) from participants recruited in cohort A were iso-
lated using density gradient centrifugation (Lymphoprep™,
Fresenius Kabi Norge AS, Halden, Norway), cryopreserved
in 10 % DMSO/90 % fetal bovine serum (FBS, GIBCO,
Life technologies) and stored in liquid nitrogen until
analysis. PBMCs from participants recruited in cohort B
were isolated in cell preparation tubes (CPT) (Becton
Dickinson, BD, New Jersey, USA) with sodium heparin
and cryopreserved in 90 % fetal calf serum (FCS, Sigma,
Missouri, USA)/10 % DMSO and stored at −145 °C until
analysis. Participants recruited in cohort A were only
included in the monocyte assay and participants recruited
in cohort B were only included in the Treg, proliferation
and intracellular cytokine assays. Therefore, all assays only
included PBMCs isolated by either of the methods.
Figure 1 gives an overview of the number of samples used
in the different assays in the study.
Table 1 Patient characteristics
Cohort A Cohort B
ATB (n = 10) LTB (n = 9) ATB (n = 23)
Age (median years, range) 28 (16–72) 43 (26–67) 29 (20–60)
Female (%) 3 (30) 4 (44) 9 (39)
Origin (%)
Africa 4 (40) 4 (44) 10 (43)
Asia 2 (20) 2 (22) 10 (43)
Europe 4 (40) 3 (33) 3 (14)
Localisation (%)
Pulmonary 10 (100) - 17 (74)
Extrapulmonarya - - 6 (26)
ESRb (median mm/
hour, range)
42 (21–77) 16 (7–23) 21 (1–103)
Characteristics of patients included at Haukeland University hospital, Bergen,
Norway (cohort A) and Oslo University hospital, Oslo, Norway (cohort B)
ATB active TB, LTB latent TB
aglandular, pericardial, pleural
bErythrocyte Sedimentation Rate
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Detection of COX-2 in monocytes
Cryovials from active and latent TB patients were thawed,
washed and resuspended in RPMI-1640 media (Sigma-Al-
drich) with 10 % FBS. PBMCs with viability <70 % were ex-
cluded from further analyses. After resting 6 h, PBMCs
were allocated to a monocyte assay for 12 h stimulation
with Lipopolysaccharide (LPS) (10 ng/mL, Sigma-Aldrich)
or unstimulated RPMI media. The cells were stained with
Live/Dead discriminator, followed by cell surface staining
of CD3, CD4, CD14, CD16 and HLA-DR and intracellular
staining of COX-2. The following live/dead discriminator
stain and directly conjugated monoclonal antibodies were
used in the monocyte assay: Live/Dead Fixable Near-IR
Dead Cell Stain kit (Life technologies), anti-CD3-PE-Cy7,
anti-CD4-Horizon V500, anti-CD14-APC, anti-CD16-PE,
anti-HLA-DR-BV421 (all from BD Bioscience) and anti-
COX-2 (Cayman Chemicals, Ann Arbor, MI, USA).
Human FOXP3 buffer set (BD bioscience) was used for
fixation and permeabilisation.
T regulatory cells and intracellular cytokine assays
PBMC’s (0.75 -1 × 106 cells/well) from patients with un-
treated active TB were rested 6 h before stimulation with
Mtb derived 6 kDa early secretory antigenic target (ESAT-
6, 2 ug/ml) and Antigen 85 (Ag85, 2 ug/ml) complex (both
15mer overlapping peptide, Genscript, HK limited; >85 %
purity). The samples were stimulated with or without the
COX-i indomethacin (25 μM, Sigma Aldrich). Staphylo-
coccal enterotoxin B (SEB) (1 ug/ml, Sigma-Aldrich) was
used as positive control and serum-free medium (AIM V;
Gibco Invitrogen, Carlsbad, CA, USA) with 0.1 % highly
purified human albumin as negative control. Due to
limited number of cells indomethacin was not added to the
SEB stimulated samples. Only PBMCs with viability >80 %
were included. Samples with COX-i were pre-treated with
indomethacin 2 h before stimulation and then incubated
for 12 and 36 h. In the 12 h assay, Brefeldin A (BFA), final
concentration 10 ug/ml (BD Bioscience) was added at time
of stimulation, whilst in the 36 h assay BFA was added for
the last 10 h to avoid prolonged incubation with potential
toxic effects of BFA [32]. In both the 12 and 36 h assay, the
cells were washed and stained with live/dead discriminator
in azide-free and serum/protein-free PBS followed by CD4,
CD3 and CD25 surface staining. The samples were washed
and fixed/permeabilized with the FOXP3 staining kit (BD
Biosciences) according to the manufacturer’s instructions.
Subsequently, cells were stained for intracellular TNF-α,
IFN-γ, IL-2 and FOXP3. The following reagents were used
in the 12 and 36 h stimulation assays for detection of
intracellular cytokines and Tregs: anti-CD4- APC- H7,
anti-CD3-PerCP-Cy5.5, anti-CD25-BV605, anti-IL-2-PE,
anti-IFN-γ- PE-Cy7, anti-TNF-α- APC, anti-FOXP3- AF
488 (all from BD Bioscience) and Fixable Viability Dye
eFluor® 450 (eBioscience, San Diego, USA).
CFSE proliferation assay
PBMCs (5 × 105cells/well) from active TB patients were
thawed and rested 6 h before labeling with Carboxyfluores-
cein succinimidyl ester (CFSE) according to manufacturer’s
procedure. In the COX-i treated samples, indomethacin
was added 2 h prior to stimulation with ESAT-6 and Ag85.
The samples were incubated for 6 days and then washed
Fig. 1 Flowchart of patient samples. Patients were included at two study locations. Cohort A (latent TB and active TB) denotes patients included
at Haukeland University Hospital, whilst cohort B denotes patients included at Oslo University Hospital. The figure also shows the distribution of
patient samples in the different assays performed in the study
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and stained for surface markers and viability staining.
Fluorochromes used in the 6 days proliferation assay; anti-
CD3-V450, anti-CD4- APC H7, anti-CD45RA -BV 605,
anti-HLA DR- APC, anti-CD25-PE, anti-CD127- PeCy7
and 7AAD- PerCP (all from BD Bioscience) and Cell-
Trace™ CFSE Cell Proliferation (Life technologies).
Flow cytometry analyses
Flow cytometric acquisition was performed on a BD FACS
Canto II and a BD LSR Fortessa flow cytometer. At least
10.000 CD4+ and CD8+ T cells were analyzed for the
intracellular analyses of cytokines and FOXP3 expression
in T cells and minimum 1.000 monocytes were required
for the analyses of COX-2 expression in monocytes. FlowJo
version 10 (TreeStar Inc, Ashland, OR, USA) was used for
data analyses. Dead cells were excluded from the lympho-
cyte and monocyte populations before applying the differ-
ent gating strategies. In the cytokine analyses, frequencies
(percentage of parent population) of Mtb antigen stimu-
lated cytokine producing T cells were calculated. Total
IFN-у+, IL-2+ or TNF-α+ describe all CD4+ or CD8+ cells
positive for the cytokine measured, while Boolean gating
strategy was used to create cytokine combinations defined
as: polyfunctional (IFN-у+IL-2+TNF-α+), double positive
(IFN-у+IL-2+ or IL-2+TNF-α+or IFN-у+TNF-α+) and sin-
gle positive (IFN-у+ or IL-2+ or TNF-α+) producing CD4+
and CD8+ T cells. Tregs were defined as FOXP3+CD25+
+CD4+ or as FOXP3+ CD45RA-CD4+ T cells [33]. In the
T cell proliferation assay, cut-off for proliferating cells was
set to the peak of the 2nd generation of CFSEdim CD4+ or
CD8+ T cells. Frequencies (percentage of parent popula-
tion) of Mtb antigen-stimulated cytokine-producing T cells,
Tregs and proliferation T cells are all shown without
subtracting background values (unstimulated controls) to
better delineate the effect of indomethacin on stimulated
versus unstimulated samples. Monocytes were defined as
“true monocytes” after exclusion of CD3+ and CD16
+HLA-DR- cells [34] and COX-2 expression (percentage
of parent population) by true monocytes was analysed. The
statistical region in the monocyte population was set by
use of COX-2 human blocking peptide (Cayman chemi-
cals) according to the manufacturer’s instructions.
Statistical analyses
Statistical analyses were performed by SPSS statistics 22
(IBM) and Statistica v 7.0 (Statsoft, Tulsa, OK, USA).
Non-parametrical statistical methods were applied. For
group-wise comparison Mann-Whitney U test was
applied and for dependent variables the two-tailed
Wilcoxon matched pair test. A significance level of 0.05
was used. All values are presented as median and inter-
quartile range [IQR]. Graphical presentations were made
using Prism V5.04 and V6 software (GraphPad, San
Diego, USA).
Results
COX 2 expression in monocytes in active and latent
tuberculosis
We first analyzed COX-2 levels in monocytes from
patients with latent or active TB (gating strategy, Fig. 2a).
Although not significant, unstimulated monocytes from
patients with active TB tended to express higher levels
of COX-2 compared to patients with latent TB (Fig. 2b).
Still, monocytes from both TB groups were able to
significantly up-regulate COX-2 expression after 12 h in
vitro LPS stimulation (Fig. 2b).
Indomethacin reduces up-regulation of Mtb antigen
induced FOXP3+CD25++ Tregs
We then assessed the in vitro effects of the COX-i indo-
methacin on Tregs from patients with active TB disease
prior to initiation of anti-TB chemotherapy (Fig. 3). FOXP3
+CD25++ Tregs were analyzed after 36-h TB antigen
stimulation, shown to be the optimal time for analyzing
FOXP3 changes in Tregs [35]. We observed a significant
up-regulation both in the fraction and the median
fluorescence intensity (MFI) of FOXP3+CD25++ Tregs in
the ESAT-6 and Ag85 stimulated CD4+ T cells with a
significant reduction in the samples treated with indometh-
acin both for the fraction of FOXP3+CD25++ Tregs (ESAT-
6; p= 0.004 and Ag85; p < 0.001) (Fig. 3a) and FOXP3 MFI
(unstim; p= 0.024 and Ag85; p= 0.023) (Fig. 3b).
Indomethacin reduces Mtb antigen induced T cell
cytokine production
To assess the effect of indomethacin on Mtb specific CD4
+ T cells, we stimulated cells with Mtb peptides with or
without addition of indomethacin and measured intracellu-
lar cytokine production after 12 and 36 h. There were
significant up-regulation of CD4+ T cell subsets producing
both IL-2, TNF-α and IFN-γ, in ESAT-6 stimulated cells
already after 12 h and in Ag85 stimulated samples also
after 36 h (Fig. 4). Indomethacin reduced the fraction of
total IL-2 producing cells after 12 h (ESAT-6; p = 0.032)
(Fig. 4a) and the fraction of total TNF-α producing cells
after 36 h stimulation (ESAT-6; p = 0.002 and Ag85; p =
0.026) (Fig. 4b), whereas no significant changes were seen
for the IFN-γ producing cells.
Single, double and polyfunctional CD4+ T cells were
also determined. After 12 h of stimulation there was no
clear pattern in response to indomethacin (Fig. 5a). The
TNF-α+IFN-γ+CD4+ cells demonstrated a slight
increase (ESAT-6; p = 0.023), whilst single TNF-α+ cells
decreased (Ag85; p = 0.043). However, after 36 h stimula-
tion, we observed a more distinct pattern in cells treated
with indomethacin with down-regulation of the follow-
ing cytokine producing CD4+ T cell subsets; IFN-γ+IL-2
+TNF-α+T cells (Ag85; p = 0.030), IL-2+TNF-α+(ESAT-
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6; p = 0.046 and Ag85; p = 0.007) and single-TNF-α+
cells (ESAT-6; p = 0.011 and Ag85; p = 0.031) (Fig. 5b).
CD8+ T cells also significantly up-regulated their
cytokine production upon Mtb antigen stimulation, but
the effect of indomethacin was less pronounced.
Overall there was a decrease in cytokine production,
but only significant for total IFN-γ+ and polyfunctional
IFN-γ-+IL-2+TNF-α+CD8+ T cells after 36 h stimula-
tion (ESAT-6; p = 0.039 and p = 0.017, respectively)
(data not shown).
Indomethacin modulates Mtb antigen induced T cell
proliferation
The proliferative capacity of Mtb peptide stimulated
CD4+ and CD8+ T cells was assessed by CFSE staining
in a 6 days stimulation assay. There was a significant in-
crease in both proliferating CD4+ (ESAT-6 and Ag85; p
< 0.001) and CD8+ T cells (ESAT-6 and Ag85 p < 0.001)
in stimulated compared to unstimulated cells (Fig. 6). A
significant, but modest, decrease of proliferating CD4+
T cells was observed in the indomethacin treated ESAT-
A
B
Fig. 2 COX-2 expression in monocytes. a Gating strategy for identification of true monocytes [34]. b Comparison of COX-2 expression in unstimulated
true monocytes in PMBCs from patients with latent TB (LTB, circles) and active TB (ATB, squares). PBMCs from patients with LTB and ATB were left
unstimulated (Unstim) or stimulated for 12 h with LPS. P- values were calculated by Wilcoxon matched pairs test for paired samples and Mann-
Whitney U test for group wise comparison (n.s = non-significant). Horizontal lines in b represent median values
Tonby et al. BMC Infectious Diseases  (2016) 16:599 Page 5 of 12
6 stimulated samples (p = 0.008) (Fig. 6a), whilst no sig-
nificant changes were seen in the Ag85 stimulated sam-
ples. For the CD8+ subsets, indomethacin likewise
reduced proliferation of Ag85 stimulated cells (p = 0.002)
(Fig. 6b). Cell surface activation markers were also
analyzed after 6 days stimulation and showed a decrease
in the fraction of activated CD25+HLA-DR+ (ESAT-6;
p = 0.011 and Ag85; p = 0.044) CD4+T cell subsets in
response to indomethacin treatment (data not shown).
Discussion
Host-directed immune modulating therapies have been
suggested as adjunct treatment in combination with
standard anti-TB antibiotics. Anti- inflammatory drugs
such as corticosteroids are already in use as adjunctive
therapy in TB meningitis with reduction of both
morbidity and mortality [36]. Non-steroid Anti- inflam-
matory drugs (NSAIDS) are already in use to relieve
symptoms in non-severe cases of paradoxical TB-IRIS
[37] and there are anecdotal reports of use of NSAIDS
in complicated cases of TB disease, however such prac-
tice is poorly documented in literature. In this study we
explored the in vitro effects of the COX-i indomethacin
on immune cells obtained from patients with active TB
disease prior to initiation of anti-TB chemotherapy. We
demonstrate for the first time that indomethacin signifi-
cantly down-regulates the fraction of Mtb antigen in-
duced Tregs as well as T cell proliferation and TNF-α
cytokine production.
First, we explored COX-2 expression in monocytes,
the major source for PGE2 production in a small cohort
of active and latent TB infection. Monocytes from pa-
tients with active TB exhibit functional and phenotypical
alterations compared with healthy controls [38, 39] that
could be restored by TB treatment [40]. Different species
of mycobacteria have been suggested to induce expres-
sion of COX-2 through different signaling pathways
[41]. To our knowledge, there are no previous studies
comparing COX-2 expression in latent versus active TB
in humans. Interestingly, we found a tendency of higher
spontaneous expression of COX-2 in the unstimulated
A
B
Fig. 3 Effect of indomethacin on TB antigen induced FOXP3+CD25++
CD4+ Tregs. PBMCs were obtained from patients with active TB (n= 17)
prior to treatment and left unstimulated (unstim) or stimulated for 36 h
with ESAT-6 or Ag85 without (open boxes) or with (hatched boxes)
addition of indomethacin. The figures show percentages of FOXP3
+CD25++ (a) and FOXP3 median fluorescence intensity (MFI) (b) in the
CD4+ cells. P- values were calculated by Wilcoxon matched pairs test.
Plots are shown as box plots together with individual data points with
median, IQR and minimum/maximum values. Significant changes
between stimulated samples with and without indomethacin are
denoted with p-values in figure. Levels of FOXP3+CD25++ CD4+ T cells
and FOXP3 MFI were significantly upregulated upon stimulation with
both E6 and Ag85 (p< 0.01, values not shown in figure)
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active TB compared to the latent TB samples, possibly
indicating an ongoing activation of the COX-2-PGE2
pathway in patients with active disease. However, as
shown by our data, also in otherwise healthy patients
with latent TB high levels of COX-2 could be expressed.
Thus, COX-2 levels in monocytes at different stages of
TB infection and any implication for disease progression
needs to be further studied in larger cohorts.
The main finding in our study was the reduction of anti-
gen induced Tregs in the indomethacin treated samples.
Of note, indomethacin also reduced the levels of FOXP3
MFI in the unstimulated samples, although to a lesser
extent than seen in the stimulated samples. This possibly
reflects an up-regulated COX expression and increased
PGE2 production in vivo in patients with active TB. There
are several reports of increased levels of Tregs in TB
disease [42–44], but the role of these immune regulatory
cells during chronic TB infection is unclear [45]. Still,
experience from animal models has proven detrimental ef-
fects of Tregs during the initial stage of infection [46]. Treg
mediated suppression of effector T cells occurs through
different mechanisms [47] and Tregs may inhibit T cell ef-
fector functions in a COX-2-PGE2 dependent manner
[14]. We find support for the use of COX-i in targeting
Tregs from studies showing that PGE2 induces FOXP3
gene expression and Treg function in human CD4+ T cells
[48]. Both the up-regulation of FOXP3 in Tregs and their
suppressive effect on effector T cells have been shown to
A B
Fig. 4 Effect of indomethacin on TB antigen induced intracellular cytokines in CD4+ T cells. Total IFN-у+, IL-2+ and TNF-α+ T cell responses in
unstimulated (Unstim), ESAT-6 and Ag85 stimulated PBMCs without (open boxes) and with (hatched boxes) indomethacin after 12 h (a, n = 18) and
36 h (b, n = 17) stimulation. PBMCs were obtained from patients with active TB prior to treatment. P- values calculated by Wilcoxon matched pairs
test. Plots are shown as box plots with individual data points with median, IQR and minimum/maximum values. Significant changes between
stimulated samples with and without indomethacin are denoted with p-values in figure
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be reversed by COX- i [14]. To our knowledge there are
no published data of immune therapy aiming to modulate
Tregs in human TB disease. There is however an ongoing
phase I/II clinical trial on COX-2-i in active TB where
Tregs will be studied (ClinicalTrials.gov Identifier: NCT0
2503839). An additional clinical trial aims to reduce the
risk of developing active TB by oral supplementation of a
probiotic containing heat-killed environmental mycobac-
teria (ClinicalTrials.gov Identifier: NCT02076139). Pre-
clinical animal models to this study have shown that the
mycobacteria delay progression to active TB in mice by
inducing PPD specific Treg populations [49]. Nevertheless,
we claim that our observed reduction of FOXP3 in indo-
methacin treated Tregs may be beneficial to the host, shift-
ing the balance towards a more effective immune response
in long-lasting and advanced TB disease.
Animal models also support PGE2 as a significant factor
in the pathogenesis of a dysfunctional hyperactivated
immune system in TB, concluding with beneficial effects of
COX-i with suppressed PGE2 concentrations; reductions
in pulmonary inflammation and bacillary load, reversal to a
Th1 cell profile and improved survival of TB infected mice
A
B
Fig. 5 Mtb antigen induced single, duo and polyfunctional cytokine producing CD4+ T cells. PBMCs were obtained from patients with active TB prior to
treatment and left unstimulated or stimulated with ESAT- 6 or Ag85 without (open boxes) or with indomethacin (hatched boxes) after 12 h (a) and 36 h
(b) stimulation (n= 18 and n= 17 respectively). Boolean gating strategy was used to create cytokine combinations of single-producing, duo-producing
and polyfunctional T cells. P- values were calculated by Wilcoxon matched pairs test ( *p <0.05, **p < 0.01). Plots are shown as box plots with median, IQR
and minimum/maximum values
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[21–24]. In contrast, one study reports reductions in mor-
bidity and mortality by augmenting PGE2 levels in Mtb-in-
fected mice [25]. The conflicting reports may be due to
differences in time since TB infection, emphasizing the
need to be aware of differential effects of PGE2 in recently
versus chronically TB infected mice.
Both CD4+ and CD8+ cytokine producing T cells play
a major role in protection and immunity against TB
disease [50], but contrasting results have made it diffi-
cult to define protective TB immunity based on cytokine
responses [51–53]. In previous clinical trials, we have
shown that HIV infected patients on antiretroviral therapy
experience an improved immune response with concomi-
tant treatment with COX2-i [26–28]. In the present study,
the COX-i indomethacin modestly reduced the Mtb anti-
gen induced CD4+ and CD8+ cytokine responses as well
as the proliferative capacity of the T cells. Our data show
that in particular the CD4+TNF-α+ cell subsets were sig-
nificantly reduced when treated with indomethacin, but
still with detectable levels. Experience from animal models
show that TNF-α is important for control of TB [54, 55]
and treatment with TNF-α blockers have been associated
with the progression from latent to active TB in humans
[56, 57]. TNF-α is essential for maintenance and formation
of the granuloma, but excess TNF-α production also con-
tributes to increased inflammation and pathology in TB
[58]. Thus, one of the purposes of immune modulating
therapy may be to decrease pathology related to excess
TNF-α production while maintaining adequate TNF-α
levels necessary for containment of Mtb [59]. Accordingly,
the decreased levels of TNF-α producing CD4+ T cells
observed in our study may constitute a potential beneficial
response in a setting with chronic untreated TB disease.
The observed reduction of cytokines and proliferative
capacity of T cells may be due to the direct effects of
indomethacin inhibiting activation of the intracellular
NF-κB pathway [60]. The NF-κB pathway is a key medi-
ator of genes involved in the control of cellular prolifera-
tion and apoptosis [61]. Inhibition of the NF-κB pathway
may be involved in the anti-inflammatory as well as the
growth inhibitory properties of certain COX-i [62, 63]
and COX-i have also been reported to inhibit NF-κB
activation in cell culture [64]. In TB, reports have shown
that TNF-α-induced NF-κB signaling pathway is central
to the Mtb-specific immune response, and regulation of
intracellular NF-κB signaling dynamics may be a key to
control TB infection [65]. Thus, in summation, one must
consider that COX-i may exert a relatively stronger
A B
Fig. 6 Effect of Indomethacin on CD4+ and CD8+ T cell proliferation. Proliferative responses measured by percentages of CFSEdim in unstimulated,
ESAT-6 and Ag85 stimulated PBMCs without (open boxes) and with (hatched boxes) indomethacin after 6 days stimulation. PBMCs were obtained from
patients with active TB prior to treatment. a CD4+ T cells (n = 23). b CD8+ T cells (n = 23). P- values were calculated by Wilcoxon matched pairs test.
Plots are shown as box plots with individual data points with median, IQR and minimum/maximum values. Significant changes between stimulated
samples with and without indomethacin are denoted with p-values in figure. %CFSEdim cells were significantly upregulated upon stimulation with
both E6 and Ag85 (p < 0.001, values not shown in figure)
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inhibitory effect on the Th1 effector cells than the antici-
pated beneficial indirect effect following reduced Treg
numbers.
There are limitations to our study. First, the relatively
small number of patients gives reduced power in the
statistical calculations and increases the risk for Type II
statistical errors. Second, multiple testing increases the risk
of type I errors. As there is no gold standard for how to
handle multiple comparisons when considering partially
dependent variables a significance level of 0.05 was used.
Due to limited numbers of samples and PBMC’s available,
we were not able to perform sorting of Tregs with more
in-depth mechanistic studies of the potential impact of the
observed decrease of indomethacin treated Tregs. For the
same reason all analysis could not be performed in the
latent TB group. Thus, future studies on COX-i should
include latent TB controls and also investigate the in vivo
effects of COX-i in clinical trials of patients in different
stages of Mtb infection.
Conclusions
In conclusion, our data indicate that indomethacin may be
used to modulate immune responses in TB infection by
reducing the fraction of Mtb specific Tregs with a con-
comitant reduction of Mtb specific cytokine responses and
T cell proliferation in active TB disease. Still, the effects of
COX-i in TB infection need further evaluation in human
models and future clinical trials should be performed to
explore the effects of COX-i as HDT options in different
settings of TB infection and disease.
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